A big transformation is happening in the global generic pharmaceutical industry. As a result, stocks of most major drug companies have done badly in the past one year.

The pharma major had posted a robust performance in the June quarter of FY19, largely aided by the launch in the US of gSuboxone, the generic version of the drug to deal opioid addiction.